- Home
- FULT vs TNGX Comparison
FULT vs TNGX Comparison
Compare FULT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FULT | TNGX |
|---|---|---|
| Founded | 1882 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.1B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FULT | TNGX |
|---|---|---|
| Price | $22.25 | $22.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $26.42 | ★ $45.18 |
| AVG Volume (30 Days) | 1.7M | ★ 3.6M |
| Earning Date | 10-21-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | ★ 32.48 | 26.89 |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $276,768,000.00 | $62,384,000.00 |
| Revenue This Year | $9.61 | N/A |
| Revenue Next Year | $6.01 | N/A |
| P/E Ratio | $21.43 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $16.86 | $6.69 |
| 52 Week High | $25.23 | $34.39 |
Technical Indicators
Market Signals| Indicator | FULT | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 40.67 | 43.98 |
| Support Level | $21.68 | $21.63 |
| Resistance Level | $22.49 | $25.93 |
| Average True Range (ATR) | 0.39 | 1.44 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 40.68 | 31.69 |
Price Performance
Historical ComparisonAbout FULT Fulton Financial Corporation
Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.